pipeline

NXL104

NXL103

preclinical

To accomplish our mission we need people who enjoy working in a dynamic...
 
 



Mature and Diverse Pipeline  

Novexel's goal is to discover and develop innovative treatments for infectious diseases which tackle the ever increasing problem of bacterial resistance.

Novexel owns all rights to the programmes outlined below, except where indicated.

Tackling serious bacterial and fungal infections is a high priority for most countries' health authorities and Novexel is focused on producing innovative products for meeting the specific needs of hospitals:



 

Print this page

23/12/2009 Novexel to be acquired by AstraZeneca...

06/11/2009 Novexel Starts Phase II Clinical Trial with NXL103 in Adults...

11/09/2009 Novexel presents 16 posters and one slide presentation at th...

> More news

> Stachyra, T., Levasseur, P., PĂ©chereau, M-C., Girard, A-M., Claudon, M., Miossec C., Black M.T. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases, Journal of Antimicrobial Chemotherapy (2009) 64 (2), 326-329.


> See all publications

> See our 2009 Factsheet
> See all our publications
> See all our press releases
> Contact us
> Access map